Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 121 to 127 of 127 entries
Sorted by: Best Match Show Resources per page
Arthroscopic Excision of Localized Nodular Tenosynovitis of Carpometacarpal Joint of Thumb: A Case Report and Review of Literature.

Journal of wrist surgery

Mane SA, Bansode AS, Karande CS, Wahegaonkar AL.
PMID: 34881110
J Wrist Surg. 2021 Mar 09;10(6):533-535. doi: 10.1055/s-0041-1725963. eCollection 2021 Dec.

Giant cell tumors of tendon sheath are classified according to their clinical presentation as localized or diffuse, and they may occur at intra-articular or extra-articular locations. Although magnetic resonance imaging is mandatory and sufficient for diagnosis in many cases,...

Cite
Mane SA, Bansode AS, Karande CS, et al. Arthroscopic Excision of Localized Nodular Tenosynovitis of Carpometacarpal Joint of Thumb: A Case Report and Review of Literature. J Wrist Surg. 2021;10(6):533-535doi: 10.1055/s-0041-1725963.
Mane, S. A., Bansode, A. S., Karande, C. S., & Wahegaonkar, A. L. (2021). Arthroscopic Excision of Localized Nodular Tenosynovitis of Carpometacarpal Joint of Thumb: A Case Report and Review of Literature. Journal of wrist surgery, 10(6), 533-535. https://doi.org/10.1055/s-0041-1725963
Mane, Satish A, et al. "Arthroscopic Excision of Localized Nodular Tenosynovitis of Carpometacarpal Joint of Thumb: A Case Report and Review of Literature." Journal of wrist surgery vol. 10,6 (2021): 533-535. doi: https://doi.org/10.1055/s-0041-1725963
Mane SA, Bansode AS, Karande CS, Wahegaonkar AL. Arthroscopic Excision of Localized Nodular Tenosynovitis of Carpometacarpal Joint of Thumb: A Case Report and Review of Literature. J Wrist Surg. 2021 Mar 09;10(6):533-535. doi: 10.1055/s-0041-1725963. eCollection 2021 Dec. PMID: 34881110; PMCID: PMC8635831.
Copy Download .nbib Format: NLM
Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD.

International journal of chronic obstructive pulmonary disease

Miller S, Teufel R, Nichols M, Davenport P, Mueller M, Silverman E, Madisetti M, Pittman M, Kelechi T, Strange C.
PMID: 34887656
Int J Chron Obstruct Pulmon Dis. 2021 Dec 03;16:3263-3273. doi: 10.2147/COPD.S326675. eCollection 2021.

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is associated with substantial functional morbidity, including activity-limiting symptoms such as dyspnea and fatigue. Self-management interventions aid in symptomatic management of COPD and have been shown to produce positive outcomes on quality of...

Cite
Miller S, Teufel R, Nichols M, et al. Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:3263-3273doi: 10.2147/COPD.S326675.
Miller, S., Teufel, R., Nichols, M., Davenport, P., Mueller, M., Silverman, E., Madisetti, M., Pittman, M., Kelechi, T., & Strange, C. (2021). Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD. International journal of chronic obstructive pulmonary disease, 163263-3273. https://doi.org/10.2147/COPD.S326675
Miller, Sarah, et al. "Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD." International journal of chronic obstructive pulmonary disease vol. 16 (2021): 3263-3273. doi: https://doi.org/10.2147/COPD.S326675
Miller S, Teufel R, Nichols M, Davenport P, Mueller M, Silverman E, Madisetti M, Pittman M, Kelechi T, Strange C. Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD. Int J Chron Obstruct Pulmon Dis. 2021 Dec 03;16:3263-3273. doi: 10.2147/COPD.S326675. eCollection 2021. PMID: 34887656; PMCID: PMC8650775.
Copy Download .nbib Format: NLM
Overexpression of alpha-1 antitrypsin in mesenchymal stromal cells improves their intrinsic biological properties and therapeutic effects in nonobese diabetic mice.

Stem cells translational medicine

Song L, Gou W, Wang J, Wei H, Lee J, Strange C, Wang H.
PMID: 32945622
Stem Cells Transl Med. 2021 Feb;10(2):320-331. doi: 10.1002/sctm.20-0122. Epub 2020 Sep 18.

Islet/β cell dysfunction and death caused by autoimmune-mediated injuries are major features of type 1 diabetes (T1D). Mesenchymal stromal cells (MSCs) have been used for the treatment of T1D in animal models and clinical trials. Based on the anti-inflammatory...

Cite
Song L, Gou W, Wang J, et al. Overexpression of alpha-1 antitrypsin in mesenchymal stromal cells improves their intrinsic biological properties and therapeutic effects in nonobese diabetic mice. Stem Cells Transl Med. 2020;10(2):320-331doi: 10.1002/sctm.20-0122.
Song, L., Gou, W., Wang, J., Wei, H., Lee, J., Strange, C., & Wang, H. (2021). Overexpression of alpha-1 antitrypsin in mesenchymal stromal cells improves their intrinsic biological properties and therapeutic effects in nonobese diabetic mice. Stem cells translational medicine, 10(2), 320-331. https://doi.org/10.1002/sctm.20-0122
Song, Lili, et al. "Overexpression of alpha-1 antitrypsin in mesenchymal stromal cells improves their intrinsic biological properties and therapeutic effects in nonobese diabetic mice." Stem cells translational medicine vol. 10,2 (2021): 320-331. doi: https://doi.org/10.1002/sctm.20-0122
Song L, Gou W, Wang J, Wei H, Lee J, Strange C, Wang H. Overexpression of alpha-1 antitrypsin in mesenchymal stromal cells improves their intrinsic biological properties and therapeutic effects in nonobese diabetic mice. Stem Cells Transl Med. 2021 Feb;10(2):320-331. doi: 10.1002/sctm.20-0122. Epub 2020 Sep 18. PMID: 32945622; PMCID: PMC7848369.
Copy Download .nbib Format: NLM
Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial.

Gastroenterology

Crinò SF, Di Mitri R, Nguyen NQ, Tarantino I, de Nucci G, Deprez PH, Carrara S, Kitano M, Shami VM, Fernández-Esparrach G, Poley JW, Baldaque-Silva F, Itoi T, Manfrin E, Bernardoni L, Gabbrielli A, Conte E, Unti E, Naidu J, Ruszkiewicz A, Amata M, Liotta R, Manes G, Di Nuovo F, Borbath I, Komuta M, Lamonaca L, Rahal D, Hatamaru K, Itonaga M, Rizzatti G, Costamagna G, Inzani F, Curatolo M, Strand DS, Wang AY, Ginès À, Sendino O, Signoretti M, van Driel LMJW, Dolapcsiev K, Matsunami Y, van der Merwe S, van Malenstein H, Locatelli F, Correale L, Scarpa A, Larghi A.
PMID: 34116031
Gastroenterology. 2021 Sep;161(3):899-909.e5. doi: 10.1053/j.gastro.2021.06.005. Epub 2021 Jun 09.

BACKGROUND AND AIMS: The benefit of rapid on-site evaluation (ROSE) on the diagnostic accuracy of endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) has never been evaluated in a randomized study. This trial aimed to test the hypothesis that in solid pancreatic...

Cite
Crinò SF, Di Mitri R, Nguyen NQ, et al. Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. Gastroenterology. 2021;161(3):899-909.e5doi: 10.1053/j.gastro.2021.06.005.
Crinò, S. F., Di Mitri, R., Nguyen, N. Q., Tarantino, I., de Nucci, G., Deprez, P. H., Carrara, S., Kitano, M., Shami, V. M., Fernández-Esparrach, G., Poley, J. W., Baldaque-Silva, F., Itoi, T., Manfrin, E., Bernardoni, L., Gabbrielli, A., Conte, E., Unti, E., Naidu, J., Ruszkiewicz, A., Amata, M., Liotta, R., Manes, G., Di Nuovo, F., Borbath, I., Komuta, M., Lamonaca, L., Rahal, D., Hatamaru, K., Itonaga, M., Rizzatti, G., Costamagna, G., Inzani, F., Curatolo, M., Strand, D. S., Wang, A. Y., Ginès, �. �., Sendino, O., Signoretti, M., van Driel, L. M. J. W., Dolapcsiev, K., Matsunami, Y., van der Merwe, S., van Malenstein, H., Locatelli, F., Correale, L., Scarpa, A., & Larghi, A. (2021). Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. Gastroenterology, 161(3), 899-909.e5. https://doi.org/10.1053/j.gastro.2021.06.005
Crinò, Stefano Francesco, et al. "Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial." Gastroenterology vol. 161,3 (2021): 899-909.e5. doi: https://doi.org/10.1053/j.gastro.2021.06.005
Crinò SF, Di Mitri R, Nguyen NQ, Tarantino I, de Nucci G, Deprez PH, Carrara S, Kitano M, Shami VM, Fernández-Esparrach G, Poley JW, Baldaque-Silva F, Itoi T, Manfrin E, Bernardoni L, Gabbrielli A, Conte E, Unti E, Naidu J, Ruszkiewicz A, Amata M, Liotta R, Manes G, Di Nuovo F, Borbath I, Komuta M, Lamonaca L, Rahal D, Hatamaru K, Itonaga M, Rizzatti G, Costamagna G, Inzani F, Curatolo M, Strand DS, Wang AY, Ginès À, Sendino O, Signoretti M, van Driel LMJW, Dolapcsiev K, Matsunami Y, van der Merwe S, van Malenstein H, Locatelli F, Correale L, Scarpa A, Larghi A. Endoscopic Ultrasound-guided Fine-needle Biopsy With or Without Rapid On-site Evaluation for Diagnosis of Solid Pancreatic Lesions: A Randomized Controlled Non-Inferiority Trial. Gastroenterology. 2021 Sep;161(3):899-909.e5. doi: 10.1053/j.gastro.2021.06.005. Epub 2021 Jun 09. PMID: 34116031.
Copy Download .nbib Format: NLM
International Forum on Walking Blood Bank Programmes: Responses.

Vox sanguinis

Martinaud C, Scorer T, Lozano M, Miles A, Fitchett G, Ba A, Wikman A, Nimberger-Hansson P, Enbuske S, Bohoněk M, Devine D, Beckett AN, Mbanya D, T'Sas F, Degueldre J, Chueca M, Dedome E, Apelseth T, Strandenes G, Wendel S, Fachini R, Olszewski A, Dupont C, Glassberg E, Shinar E, Taylor AL, Corley JB, Nadarajan VS, Dunbar N.
PMID: 33939177
Vox Sang. 2021 Sep;116(8):e44-e70. doi: 10.1111/vox.13102. Epub 2021 May 03.

No abstract available.

Cite
Martinaud C, Scorer T, Lozano M, et al. International Forum on Walking Blood Bank Programmes: Responses. Vox Sang. 2021;116(8):e44-e70doi: 10.1111/vox.13102.
Martinaud, C., Scorer, T., Lozano, M., Miles, A., Fitchett, G., Ba, A., Wikman, A., Nimberger-Hansson, P., Enbuske, S., Bohoněk, M., Devine, D., Beckett, A. N., Mbanya, D., T'Sas, F., Degueldre, J., Chueca, M., Dedome, E., Apelseth, T., Strandenes, G., Wendel, S., Fachini, R., Olszewski, A., Dupont, C., Glassberg, E., Shinar, E., Taylor, A. L., Corley, J. B., Nadarajan, V. S., & Dunbar, N. (2021). International Forum on Walking Blood Bank Programmes: Responses. Vox sanguinis, 116(8), e44-e70. https://doi.org/10.1111/vox.13102
Martinaud, Christophe, et al. "International Forum on Walking Blood Bank Programmes: Responses." Vox sanguinis vol. 116,8 (2021): e44-e70. doi: https://doi.org/10.1111/vox.13102
Martinaud C, Scorer T, Lozano M, Miles A, Fitchett G, Ba A, Wikman A, Nimberger-Hansson P, Enbuske S, Bohoněk M, Devine D, Beckett AN, Mbanya D, T'Sas F, Degueldre J, Chueca M, Dedome E, Apelseth T, Strandenes G, Wendel S, Fachini R, Olszewski A, Dupont C, Glassberg E, Shinar E, Taylor AL, Corley JB, Nadarajan VS, Dunbar N. International Forum on Walking Blood Bank Programmes: Responses. Vox Sang. 2021 Sep;116(8):e44-e70. doi: 10.1111/vox.13102. Epub 2021 May 03. PMID: 33939177.
Copy Download .nbib Format: NLM
Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy.

JACC. Case reports

Klein EC, Rubinstein J, Strande JL.
PMID: 34316787
JACC Case Rep. 2019 Aug 21;1(2):213-217. doi: 10.1016/j.jaccas.2019.07.008. eCollection 2019 Aug.

A 56-year-old man with multiple cardiac manifestations of type 1 myotonic dystrophy, including severe, nonischemic cardiomyopathy, presented in refractory cardiogenic shock requiring inotropic therapy. Given his wishes to die without having any intravenous medications, he was started on oral...

Cite
Klein EC, Rubinstein J, Strande JL. Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy. JACC Case Rep. 2019;1(2):213-217doi: 10.1016/j.jaccas.2019.07.008.
Klein, E. C., Rubinstein, J., & Strande, J. L. (2019). Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy. JACC. Case reports, 1(2), 213-217. https://doi.org/10.1016/j.jaccas.2019.07.008
Klein, Evan C, et al. "Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy." JACC. Case reports vol. 1,2 (2019): 213-217. doi: https://doi.org/10.1016/j.jaccas.2019.07.008
Klein EC, Rubinstein J, Strande JL. Probenecid: An Oral Inotrope for End-Stage Heart Failure in a Case With Myotonic Dystrophy. JACC Case Rep. 2019 Aug 21;1(2):213-217. doi: 10.1016/j.jaccas.2019.07.008. eCollection 2019 Aug. PMID: 34316787; PMCID: PMC8301499.
Copy Download .nbib Format: NLM
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.

Investigational new drugs

Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA.
PMID: 34515877
Invest New Drugs. 2022 Feb;40(1):115-123. doi: 10.1007/s10637-021-01175-6. Epub 2021 Sep 13.

PURPOSE: Targeting the vascular endothelial growth factor (VEGF) pathway improves progression free survival in multiple advanced malignancies but durable responses are uncommon. Inhibition of the VEGF pathway at multiple levels of signal transduction may improve clinical outcomes. Preclinical data...

Cite
Hubbard JM, Yin J, Schenk EL, et al. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2021;40(1):115-123doi: 10.1007/s10637-021-01175-6.
Hubbard, J. M., Yin, J., Schenk, E. L., Qin, R., Reid, J. M., Strand, C., Fiskum, J., Menefee, M., Lin, G., Doyle, L. A., Ivy, P., Erlichman, C., Adjei, A., Haluska, P., & Costello, B. A. (2022). Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Investigational new drugs, 40(1), 115-123. https://doi.org/10.1007/s10637-021-01175-6
Hubbard, Joleen M, et al. "Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies." Investigational new drugs vol. 40,1 (2022): 115-123. doi: https://doi.org/10.1007/s10637-021-01175-6
Hubbard JM, Yin J, Schenk EL, Qin R, Reid JM, Strand C, Fiskum J, Menefee M, Lin G, Doyle LA, Ivy P, Erlichman C, Adjei A, Haluska P, Costello BA. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. Invest New Drugs. 2022 Feb;40(1):115-123. doi: 10.1007/s10637-021-01175-6. Epub 2021 Sep 13. PMID: 34515877.
Copy Download .nbib Format: NLM
Showing 121 to 127 of 127 entries